CRISPR/Cas9: a nebula of patents

Discover an extract from the Immunowatch, a one-of-a-kind newsletter in the field of immunotherapy published by our partner Mabdesign, which contains an in-depth analysis on CRISPR/Cas9 patents, and its challenging licensing landscape, conducted by Lucile Vernoux and Nicolas Bouquin.

Regimbeau, Paris

CRISPR-Cas9 technology (“Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9 (Cas9)”) is already one of the most important scientific developments of this century. Its applications are wide and varied, and touch almost every aspect of biology. It has the ability to transform such important fields as e.g., agriculture and medicine. This technology is in particular poised to revolutionise medicine, with the potential to cure a range of genetic diseases, including neurodegenerative disease, blood disorders, cancer, and ocular disorders.

CRISPR-Cas9 is the most potent gene-editing tools to date. Sections of nucleic acids are edited in cells by insertion, deletion, or replacement at a specific target sequence. It is precise, fast, easy to implement, cheap, and uses components readily accessible.

Read more

Published by

Lucile Vernoux, Ph.D

French Patent Attorney
European Patent Attorney

Nicolas Bouquin, Ph.D

Senior Associate